Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Sagimet Biosciences Inc.

< Previous 1 2 Next >
Sagimet Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers BRNS RCUS SGMT SNDX TRVN ZURA
Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers IPSC MIRM RPHM SGMT
Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
Sagimet Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
Sagimet Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
Sagimet Biosciences Announces Acceptance of Two Abstracts at AASLD - The Liver Meeting® 2023
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
Sagimet Biosciences To Present at the H.C. Wainwright 7th Annual NASH Investor Conference
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
Sagimet Biosciences Announces Completion of Enrollment of 120 Patients for Phase 3 Clinical Trial by Its Partner Ascletis of Denifanstat Combined with Bevacizumab for Treatment of Recurrent Glioblastoma
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
Sagimet Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate Updates
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
Sagimet Biosciences Announces Closing of Underwriters’ Option to Purchase Additional Shares of Series A Common Stock in Connection with its Upsized Initial Public Offering
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
Sagimet Biosciences Announces Leadership Changes
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
Sagimet Biosciences Announces Pricing of Upsized Initial Public Offering
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Presents Positive Phase 2b FASCINATE-2 Clinical Trial Interim Data for Denifanstat for the Treatment of NASH at EASL Congress 2023
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences to Present Interim Data from Phase 2b Trial of Denifanstat in NASH at EASL Congress 2023
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Announces Presentation of Additional Phase 2 Data on Denifanstat Identifying a Predictive Metabolic Signature in NASH Patients at EASL’s International Liver Congress (ILC) 2022
From Sagimet Biosciences Inc.
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.